Table 4.
Distributions of rs2070874, rs2243248, and rs1800925 polymorphisms in CP patients and healthy controls.
| SNP | Genotype/allele | CP patients N = 440 (%) |
Controls N = 324 (%) |
Crude OR (95% CI)† | P value‡ | Adjusted OR (95% CI)a | P value‡ |
|---|---|---|---|---|---|---|---|
| rs2070874 | T/T∗ | 289 (65.7) | 210 (64.8) | 1 | 1 | ||
| C/T | 130 (29.5) | 96 (29.6) | 0.984 (0.716–1.352) | 0.935 | 1.062 (0.266–4.244) | 0.933 | |
| C/C | 21 (4.8) | 18 (5.6) | 0.848 (0.441–1.631) | 0.619 | 1.082 (0.215–5.460) | 0.924 | |
| T∗ | 708 (80.5) | 516 (79.6) | 1 | 1 | |||
| C | 172 (19.5) | 132 (20.4) | 0.950 (0.737–1.224) | 0.698 | 1.216 (0.455–3.247) | 0.696 | |
|
| |||||||
| rs2243248 | T/T∗ | 401 (91.1) | 261 (80.6) | 1 | 1 | ||
| G/T | 38 (8.6) | 57 (17.6) | 0.434 (0.280–0.673) | 0.001 | 0.276 (0.237–0.322) | 0.002 | |
| G/G | 1 (2.3) | 6 (1.8) | 0.108 (0.013–0.906) | 0.018 | 0.109 (0.085–0.140) | 0.001 | |
| T∗ | 840 (95.5) | 579 (89.4) | 1 | 1 | |||
| G | 40 (4.5) | 69 (10.6) | 0.400 (0.267–0.598) | 0.001 | 0.321 (0.290–0.355) | 0.001 | |
|
| |||||||
| rs1800925 | C/C∗ | 330 (75.0) | 227 (70.1) | 1 | 1 | ||
| C/T | 96 (21.8) | 93 (28.7) | 0.710 (0.510–0.989) | 0.050 | 0.826 (0.615–1.109) | 0.204 | |
| T/T | 14 (3.2) | 4 (1.2) | 2.408 (0.782–7.408) | 0.145 | 2.091 (1.230–3.556) | 0.301 | |
| C∗ | 756 (85.9) | 547 (84.4) | 1 | 1 | |||
| T | 124 (14.1) | 101 (15.6) | 0.888 (0.668–1.181) | 0.422 | 1.005 (0.736–1.371) | 0.977 | |
aAdjusted for gender and age.
†OR, odds ratio; CI, confidence interval.
‡Significant difference was accepted at P < 0.05.
∗Homozygous genotypes were used as reference group.